Last edition
News about "Sunshine Biopharma Enters Canadian Biosimilars Mar"
Sunshine Biopharma Enters Canadian Biosimilars Market with Launch of Niopeg
Niopeg is a biosimilar to Neulasta (Pegfilgrastim), a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (filgrastim), used to reduce infection risk in cancer patients undergoing chemotherapy.
Sunshine Biopharma Enters Canadian Biosimilars Mar | 04/07/2025 | By Darshana | 227
Sunshine Biopharma Enters Canadian Biosimilars Market with Launch of Niopeg
Niopeg is a biosimilar to Neulasta (Pegfilgrastim), a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (filgrastim), used to reduce infection risk in cancer patients undergoing chemotherapy.
Sunshine Biopharma Enters Canadian Biosimilars Mar | 04/07/2025 | By Darshana | 227
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy